CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 19, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will present...

- Sebetralstat Phase 3 KONFIDENT Clinical Trial Achieves Target Enrollment; Data Readout on Track for Q4 - - Preparations Continue for NDA filing H1 2024 and Rapid Commercialization Upon Approval - CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep....

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Aug. 28, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Aug. 2, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the grant of an inducement award to the Company’s recently appointed Chief Commercial Officer, Nicole Sweeny . In connection with Ms....

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jul. 25, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced today the appointment...

– Real-world data show people with HAE consistently recognize onset of attacks and understand the need for early attack treatment - – When provided similar efficacy and safety profiles for oral and injectable on-demand treatments for HAE attacks, adults and adolescents express a strong preference...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jul. 14, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of...

– Sebetralstat Phase 3 KONFIDENT Clinical Trial Achieves Target Enrollment; Data Readout Expected in Q4 – – Company Funded Into 2025 With NDA Planned for H1 2024 – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jul. 7, 2023-- KalVista Pharmaceuticals, Inc....

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jul. 5, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted two newly-hired employees inducement options to purchase an aggregate of 13,000 shares of...

– Sebetralstat pharmacokinetic and pharmacodynamic data support globalization of the KONFIDENT phase 3 clinical trial and use in short-term prophylaxis – – Real-world patient data show significant burden from HAE still remains on patients receiving modern long-term prophylaxis and challenges...